Using Physiologically Based Pharmacokinetic (PBPK) Modeling to Evaluate the Impact of Pharmaceutical Excipients on Oral Drug Absorption: Sensitivity Analyses

被引:27
|
作者
Chow, Edwin Chiu Yuen [1 ,2 ]
Talattof, Arjang [1 ,2 ]
Tsakalozou, Eleftheria [1 ,2 ]
Fan, Jianghong [1 ,2 ]
Zhao, Liang [1 ,2 ]
Zhang, Xinyuan [1 ,2 ]
机构
[1] US FDA, Div Quantitat Methods & Modeling, Off Res & Stand, Off Gener Drugs, Silver Spring, MD 20993 USA
[2] 10903 New Hampshire Ave,Bldg 75,Room 4690, Silver Spring, MD 20993 USA
来源
AAPS JOURNAL | 2016年 / 18卷 / 06期
关键词
Biopharmaceutics Classification System (BCS); excipients; gastrointestinal transporters; oral drug absorption; PBPK modeling; BIOPHARMACEUTICS CLASSIFICATION-SYSTEM; PEPTIDE TRANSPORTER PEPT1; COMMONLY USED EXCIPIENTS; P-GLYCOPROTEIN; CREMOPHOR EL; CACO-2; CELLS; BIOAVAILABILITY; PERMEABILITY; SURFACTANTS; METABOLISM;
D O I
10.1208/s12248-016-9964-4
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Drug solubility, effective permeability, and intestinal metabolism and transport are parameters that govern intestinal bioavailability and oral absorption. However, excipients may affect the systemic bioavailability of a drug by altering these parameters. Thus, parameter sensitivity analyses using physiologically based pharmacokinetic (PBPK) models were performed to examine the potential impact of excipients on oral drug absorption of different Biopharmaceutics Classification System (BCS) class drugs. The simulation results showed that changes in solubility had minimal impact on C-max and AUC(0-t) of investigated BCS class 1 and 3 drugs. Changes in passive permeability altered C-max more than AUC(0-t) for BCS class 1 drugs but were variable and drug-specific across different BCS class 2 and 3 drugs. Depending on the drug compounds for BCS class 1 and 2 drugs, changes in intestinal metabolic activity altered C-max and AUC(0-t). Reducing or increasing influx and efflux transporter activity might likely affect C-max and AUC(0-t) of BCS class 2 and 3 drugs, but the magnitude may be drug dependent. Changes in passive permeability and/or transporter activity for BCS class 2 and 3 drugs might also have a significant impact on fraction absorbed and systemic bioavailability while changes in intestinal metabolic activity may have an impact on gut and systemic bioavailability. Overall, we demonstrate that PBPK modeling can be used routinely to examine sensitivity of bioavailability based on physiochemical and physiological factors and subsequently assess whether biowaiver requirements need consideration of excipient effects for immediate release oral solid dosage forms.
引用
收藏
页码:1500 / 1511
页数:12
相关论文
共 50 条
  • [21] Analysis of the impact of controlled release formulations on oral drug absorption, gut wall metabolism and relative bioavailability of CYP3A substrates using a physiologically-based pharmacokinetic model
    Olivares-Morales, Andres
    Kamiyama, Yoshiteru
    Darwich, Adam S.
    Aarons, Leon
    Rostami-Hodjegan, Amin
    EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2015, 67 : 32 - 44
  • [22] A Bayesian population physiologically based pharmacokinetic absorption modeling approach to support generic drug development: application to bupropion hydrochloride oral dosage forms
    Hsieh, Nan-Hung
    Bois, Frederic Y.
    Tsakalozou, Eleftheria
    Ni, Zhanglin
    Yoon, Miyoung
    Sun, Wanjie
    Klein, Martin
    Reisfeld, Brad
    Chiu, Weihsueh A.
    JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, 2021, 48 (06) : 893 - 908
  • [23] Application of Physiologically Based Absorption Modeling to Characterize the Pharmacokinetic Profiles of Oral Extended Release Methylphenidate Products in Adults
    Yang, Xiaoxia
    Duan, John
    Fisher, Jeffrey
    PLOS ONE, 2016, 11 (10):
  • [24] Teaching of drug disposition using physiologically based pharmacokinetic modeling software: GastroPlus as an educational tool
    Morningstar-Kywi, Noam
    Morris, Denise N.
    Romero, Rebecca M.
    Haworth, Ian S.
    ADVANCES IN PHYSIOLOGY EDUCATION, 2023, 47 (04) : 718 - 725
  • [25] A Bottom-up Approach for Mutant and Wild Type Collies Using Physiologically Based Pharmacokinetic (PBPK) Modeling: A Case Study Using Loperamide
    Charlotte Cross
    Marilyn N. Martinez
    Devendra Pade
    Michael J. Myers
    Sibylle Neuhoff
    The AAPS Journal, 27 (4)
  • [26] Prediction of CYP-Mediated Drug Interaction Using Physiologically Based Pharmacokinetic Modeling: A Case Study of Salbutamol and Fluvoxamine
    Marques, Lara
    Vale, Nuno
    PHARMACEUTICS, 2023, 15 (06)
  • [27] Evaluation of Drug-Drug Interactions Between Clarithromycin and Direct Oral Anticoagulants Using Physiologically Based Pharmacokinetic Models
    Yang, Zhuan
    Qu, Yuchen
    Sun, Yewen
    Pan, Jie
    Zhou, Tong
    Yu, Yunli
    PHARMACEUTICS, 2024, 16 (11)
  • [28] Utility of Physiologically Based Pharmacokinetic Modeling to Investigate the Impact of Physiological Changes of Pregnancy and Cancer on Oncology Drug Pharmacokinetics
    Yang, Xinxin
    Grimstein, Manuela
    Pressly, Michelle
    Fletcher, Elimika Pfuma
    Shord, Stacy
    Leong, Ruby
    PHARMACEUTICS, 2023, 15 (12)
  • [29] Physiologically-Based Pharmacokinetic Model on the Oral Drug Absorption in Roux-en-Y Gastric Bypass Bariatric Patients: Amoxicillin Tablet and Suspension
    Montanha, Maiara Camotti
    Diniz, Andrea
    Elvas Neves Silva, Nuno Miguel
    Kimura, Elza
    Paixao, Paulo
    MOLECULAR PHARMACEUTICS, 2019, 16 (12) : 5025 - 5034
  • [30] Quantitative Assessment of Elagolix Enzyme-Transporter Interplay and Drug-Drug Interactions Using Physiologically Based Pharmacokinetic Modeling
    Chiney, Manoj S.
    Ng, Juki
    Gibbs, John P.
    Shebley, Mohamad
    CLINICAL PHARMACOKINETICS, 2020, 59 (05) : 617 - 627